ATLANTA (March 24, 2010) – Piedmont Hospital announced today the availability of a clinical research study for qualifying participants. The study will test the effectiveness and tolerability of an investigational anti-cancer immunotherapy.
To qualify, participants must have early stage non-small cell lung cancer, which has been surgically removed in the last 12 weeks. The tumor must be completely removed to qualify for this study.
In addition to standard treatment, study participants receive frequent tumor assessments and study-related medical care. Participants may potentially have access to medication and receive compensation for approved travel expenses.
The investigational treatment and medical care required solely for the research study will be provided by the study sponsor GlaxoSmithKline.
For more information and to see if you qualify, visit piedmontcancer.org or call 404-425-7943.